The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
Abstract
OBJECTIVE: The authors sought to compare the effects of olanzapine, quetiapine, and risperidone on neurocognitive function in patients with early psychosis. METHOD: In a 52-week double-blind, multicenter study, 400 patients early in the course of psychotic illness (<5 years) were randomly assigned to treatment with olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day), or risperidone (0.5-4 mg/day). The mean modal daily dose was 11.7 mg (SD=5.3) for olanzapine, 506 mg (SD=215) for quetiapine, and 2.4 mg (SD=1.0) for risperidone. A total of 224 patients completed neurocognitive assessments at baseline and at 12 weeks, and 81 patients also completed them at 52 weeks. Neurocognitive composite scores were calculated from the neurocognitive battery used in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and from the Brief Assessment of Cognition in Schizophrenia. RESULTS: At week 12, there was significant improvement in neurocognition for each treatment (p<0.01), but no significant overall difference between treatments. Composite z score improvements on the CATIE neurocognitive battery were 0.17 for olanzapine, 0.33 for quetiapine, and 0.32 for risperidone. Composite z score improvements on the Brief Assessment of Cognition in Schizophrenia were 0.19 for olanzapine, 0.34 for quetiapine, and 0.22 for risperidone. Statistically significant relationships between improvements in neurocognition and functional outcome were observed at weeks 12 and 52. CONCLUSIONS: Olanzapine, quetiapine, and risperidone all produced significant improvements in neurocognition in early-psychosis patients. Although cognitive improvements were modest, their clinical importance was suggested by relationships with improvements in functional outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,395
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
What are the functional consequences of neurocognitive deficits in schizophrenia?
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.321 · Cited by 3,516
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
Neurocognitive deficit in schizophrenia: A quantitative review of the evidence.
Heinrichs, R. W., & Zakzanis, K. K. (1998) · Neuropsychology · doi:10.1037/0894-4105.12.3.426 · Cited by 2,798
A Rating Scale for Drug-Induced Akathisia
Barnes, T. R. E. (1989) · British Journal of Psychiatry · doi:10.1192/bjp.154.5.672 · Cited by 2,170
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
The Quality of Life Scale: An Instrument for Rating the Schizophrenic Deficit Syndrome
Heinrichs, D. W., Hanlon, T. E., & Carpenter, W. T. (1984) · Schizophrenia Bulletin · doi:10.1093/schbul/10.3.388 · Cited by 1,688
Keefe, R. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.011 · Cited by 1,573
Identification of separable cognitive factors in schizophrenia
Nuechterlein, K. H., Barch, D. M., Gold, J. M., Goldberg, T. E., Green, M. F., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.007 · Cited by 1,304
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Keefe, R. S. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.633 · Cited by 1,065
Self-citationGreen, M. F., Nuechterlein, K. H., Gold, J. M., Barch, D. M., Cohen, J., Essock, S., Fenton, W. S., Frese, F., Goldberg, T. E., Heaton, R. K., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.06.023 · Cited by 919
Self-citationKeefe, R. S. E., Silva, S. G., Perkins, D. O., & Lieberman, J. A. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033374 · Cited by 693
Self-citationStudies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment
Harvey, P. D., & Keefe, R. S. E. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.176 · Cited by 620
Self-citationWoodward, N. D., Purdon, S. E., Meltzer, H. Y., & Zald, D. H. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114570500516x · Cited by 605
Bilder, R. M., Goldman, R. S., Volavka, J., Czobor, P., Hoptman, M., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J., Kunz, M., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1018 · Cited by 538
Self-citationBaseline Neurocognitive Deficits in the CATIE Schizophrenia Trial
Keefe, R. S. E., Bilder, R. M., Harvey, P. D., Davis, S. M., Palmer, B. W., Gold, J. M., Meltzer, H. Y., Green, M. F., Miller, D. D., Canive, J. M., et al. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301072 · Cited by 472
Self-citationPurdon, S. E. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.249 · Cited by 469
Generalized Cognitive Deficits in Schizophrenia: A Study of First-Episode Patients
Mohamed, S., Paulsen, J. S., O'Leary, D., Arndt, S., & Andreasen, N. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.8.749 · Cited by 432
Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.799 · Cited by 397
Hagger, C., Buckley, P., Kenny, J. T., Friedman, L., Ubogy, D., & Meltzer, H. Y. (1993) · Biological Psychiatry · doi:10.1016/0006-3223(93)90043-d · Cited by 393
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Self-citationHarvey, P. D., Howanitz, E., Parrella, M., White, L., Davidson, M., Mohs, R. C., Hoblyn, J., & Davis, K. L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.8.1080 · Cited by 338
Neuropsychological functioning of first-episode schizophreniform patients
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.7.898 · Cited by 322
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Lewine, R. R. J., Yurgelun-Todd, D. A., Gur, R. C., Tohen, M., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.985 · Cited by 314
Self-citationBuchanan, R. W., Holstein, C., & Breier, A. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)90082-5 · Cited by 281
Do Specific Neurocognitive Deficits Predict Specific Domains of Community Function in Schizophrenia?
VELLIGAN, D. I., BOW-THOMAS, C. C., MAHURIN, R. K., MILLER, A. L., & HALGUNSETH, L. C. (2000) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200008000-00007 · Cited by 247
The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone
Green, M. F., Marder, S. R., Glynn, S. M., McGurk, S. R., Wirshing, W. C., Wirshing, D. A., Liberman, R. P., & Mintz, J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01370-7 · Cited by 202
Does cognitive function improve with quetiapine in comparison to haloperidol?
Velligan, D. I., Newcomer, J., Pultz, J., Csernansky, J., Hoff, A. L., Mahurin, R., & Miller, A. L. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00268-7 · Cited by 183
Purdon, S. E., MALLA, A. K., Labelle, A., & Lit, W. (2001) · PubMed · Cited by 177
Keefe, R. S. E., Poe, M. P., Walker, T. M., & Harvey, P. D. (2006) · Journal of Clinical and Experimental Neuropsychology · doi:10.1080/13803390500360539 · Cited by 175
Self-citationKeefe, R. S. E., Young, C. A., Rock, S. L., Purdon, S. E., Gold, J. M., & Breier, A. F. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.038 · Cited by 173
Self-citationHill, S. (2004) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00213-5 · Cited by 168
Harvey, P. D., Rabinowitz, J., Eerdekens, M., & Davidson, M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1888 · Cited by 161
Harvey, P. D., Green, M. F., McGurk, S. R., & Meltzer, H. Y. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1342-5 · Cited by 156
Muscarinic mechanisms of antipsychotic atypicality
Bymaster, F. P., Felder, C. C., Tzavara, E. T., Nomikos, G. G., Calligaro, D. O., & McKinzie, D. L. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.008 · Cited by 146
Long-Term Neurocognitive Effects of Olanzapine or Low-Dose Haloperidol in First-Episode Psychosis
Keefe, R. S. E., Seidman, L. J., Christensen, B. K., Hamer, R. M., Sharma, T., Sitskoorn, M. M., Rock, S. L., Woolson, S., Tohen, M. F., Tollefson, G. D., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.022 · Cited by 131
Self-citationLee, M., Jayathilake, K., & Meltzer, H. Y. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00145-5 · Cited by 120
A neuropsychological study of early onset schizophrenia
Hoff, A. L., Harris, D. S., Faustman, W. O., Beal, M., DeVilliers, D., Mone, R. D., Moses, J. A., & Csernansky, J. G. (1996) · Schizophrenia Research · doi:10.1016/0920-9964(95)00065-8 · Cited by 85
Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia.
Sweeney, J., Haas, G., & Li, S. (1992) · Schizophrenia bulletin · doi:10.1093/schbul/18.2.283 · Cited by 79
Self-citationCognitive Impairment in Schizophrenia and Implications of Atypical Neuroleptic Treatment
Harvey, P. D., & Keefe, R. S. E. (1997) · CNS Spectrums · doi:10.1017/s1092852900005034 · Cited by 72
Self-citationSax, K. W., Strakowski, S. M., & Keck, P. E. (1998) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00067-x · Cited by 48
Effects of Clozapine on Psychiatric Symptoms, Cognition, and Functional Outcome in Schizophrenia
Manschreck, T. C., Redmond, D. A., Candela, S. F., & Maher, B. A. (1999) · Journal of Neuropsychiatry · doi:10.1176/jnp.11.4.481 · Cited by 44
Cited by
Insel, T. R. (2010) · Nature · doi:10.1038/nature09552 · Cited by 1,783
Neurocognition in first-episode schizophrenia: a meta-analytic review.
Mesholam-Gately, R. I., Giuliano, A. J., Goff, K. P., Faraone, S. V., & Seidman, L. J. (2009) · Neuropsychology · doi:10.1037/a0014708 · Cited by 1,130
Hasan, A., Falkai, P., Wobrock, T., Lieberman, J., Glenthoj, B., Gattaz, W. F., Thibaut, F., Möller, H.-J., & the Wfsbp Task Force on Treatment Guidelines for Schizophrenia (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.696143 · Cited by 637
Self-citationHill, S. K., Reilly, J. L., Keefe, R. S. E., Gold, J. M., Bishop, J. R., Gershon, E. S., Tamminga, C. A., Pearlson, G. D., Keshavan, M. S., & Sweeney, J. A. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12101298 · Cited by 354
Self-citationNorms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
KEEFE, R., HARVEY, P., GOLDBERG, T., GOLD, J., WALKER, T., KENNEL, C., & HAWKINS, K. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.03.024 · Cited by 342
Self-citation
Metadata
- Authors
- Keefe, R. S. E., Sweeney, J. A., Gu, H., Hamer, R. M., Perkins, D. O., McEvoy, J. P., & Lieberman, J. A.
- Venue
- American Journal of Psychiatry
- Published
- 2007-07
- Volume
- 164
- Issue
- 7
- Pages
- 1061-1071
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W1985065973
- Cited by
- 276
- References
- 45
- FWCI
- 16.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.